K. M. Wilson

This study uses conditional lethality profiling in human plasma-like medium to identify drug mechanisms and interactions with nutrients, revealing new therapeutic strategies.

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

This study identifies mTOR inhibition as a strategy to overcome RSK3-mediated resistance to BET inhibitors in small cell lung cancer, enhancing apoptosis and antitumor efficacy.

This study investigates how olfactory cues affect pup vocalizations in California mice, finding differences based on litter size, sex, and odor type.

This paper develops a cross-platform Bayesian optimization system to accelerate biological assay development, reducing costs and time compared to brute force methods.

The paper identifies 319 compounds with anti-SARS-CoV-2 activities through a high-throughput screen, including 91 approved drugs and 49 investigational drugs, with 230 compounds previously unreported.

The paper develops an AlphaLISA assay to measure SARS-CoV-2 spike RBD-ACE2 binding and identifies 25 drug candidates that disrupt this interaction.

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

The paper profiles cytotoxicity of over 100,000 compounds across normal and cancer cell lines to identify cytotoxic compounds and improve screening efficiency.